Filing Flows › Attovia Therapeutics (ATTO) › Q2 2026
Attovia Therapeutics (ATTO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Sep 2, 2026
Attovia Therapeutics (ATTO) reported revenue of $450K for the second quarter 2026 (Q2 2026).
Revenue$450K
Year over year—
Quarter over quarter—
Operating margin—
Net earnings−$20.7M
Attovia Therapeutics, Q2 2026: revenue $450K, net loss $20.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $450K | — | — |
| Operating profit | −$21.8M | — | — |
| Net earnings | −$20.7M | — | — |
What changed
Revenue was $450K in Q2 2026.
Operating costs exceeded revenue by $21.8M, an operating margin of -4845.1%. The quarter ended with a net loss of $20.7M.
Questions
What was Attovia Therapeutics' revenue in the second quarter 2026?
Attovia Therapeutics (ATTO) reported revenue of $450K for the second quarter 2026 (Q2 2026).